Raymond James & Associates Arcellx, Inc. Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
A detailed history of Raymond James & Associates transactions in Arcellx, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 4,992 shares of ACLX stock, worth $455,120. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,992
Previous 4,914
1.59%
Holding current value
$455,120
Previous $271,000
53.51%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding ACLX
# of Institutions
205Shares Held
44.2MCall Options Held
2.23MPut Options Held
907K-
Paradigm Biocapital Advisors LP New York, NY4MShares$365 Million12.04% of portfolio
-
Perceptive Advisors LLC New York, NY3.89MShares$355 Million8.48% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$341 Million23.89% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$321 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.46MShares$224 Million0.0% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $3.99B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...